← brief for 2026-08-26 · Slowing decline

Prescription of SGLT-2 inhibitors alone or in combination with RAS-inhibitors in patients with diabetes mellitus and comorbid cardiovascular disease, chronic kidney disease or cardiorenal disease: a real-world evidence study from the REPOSI registry.

Article C Peer reviewed Observational

Key takeaways

This real-world study followed 1372 older adults with diabetes and heart or kidney disease to see how SGLT-2 inhibitors, alone or with other blood pressure drugs, affected their health. Because it looked at existing medical records and not a planned experiment, it shows a link between the drugs and better outcomes but cannot prove cause and effect.

Who did this work

Lido P · Ratti S · Ronchetti C · Infante M · Tesauro M · Mannucci PM · Staszewsky LI · Nobili A · Tettamanti M · REPOSI Investigators

Source

Article · PubMed, the drug frontier · 2026 Aug 25
https://pubmed.ncbi.nlm.nih.gov/42642609/